Introduction: Precision medicine is an important milestone toward the attainment
Achieving the vision of personalized medicine through the precision medicine initiative 1 requires a comprehensive, multidisciplinary approach to support evidence-based biomedical research. Recent research advances in using big data combined with development of artificial intelligence (AI) have accelerated the pace of translational research. Therefore, the use of real-world data (RWD) such as diagnosis, treatment, and images in hospital information system (HIS), combined with insurance claim data, is becoming increasingly important to support evidenced-based translational research. While RWD are often not clean enough or optimized for direct research use, realworld "evidence" 2,3 is highly valued by major regulatory agencies around the world. Regulatory approval of diagnostic kits, devices, drugs, and biologics requires high-quality datasets from clinical trials to provide needed evidence. Furthermore, because the amount of data can be collected in a single institution is quite limited, 4 the formation of an interdisciplinary team and sharing of data are needed to obtain sufficient datasets to support rare diseases research 5 and precision medicine initiatives. 6 Precision medicine research is a challenge not only due to data sharing requirements but also because certified genetic testing services that include diagnosis and interpretation are expensive. Other rate-limiting steps are the knowledge generation processes associated with diagnosis and classification of diseases to find optimal, individualized treatments and development of clinically validated biomarkers. It is, therefore, important to establish a full learning cycle ensuring that the learning is continuous, knowledge informs improvements, and a true learning health system (LHS) is formed.
Taichung Veterans General Hospital (TCVGH) has established five data marts from their de-identified Electronic Health Record (EHR) data warehouse: the geriatrics database, the cancer registry database (CRD), the health examination database, the health insurance claim database, and the internal clinical database (see Figure 1 ). These databases were established primarily for use by hospital administration and management and for investigator-initiated research. Any investigator may apply to receive de-identified data from these databases for use in research. For example, to propose and conduct any disease-specific translational study, such as a study of colon cancer, a new dataset can be easily constructed by using combinations of data from the five internal databases, upon Institutional Review Board (IRB) approval, The CIMS has four subsystems:
(1) a protocol tracking and management system (PTMS), which is an electronic institutional review board system (eIRB) developed to track and manage the life cycle of clinical research and trial protocols from submission to approval and for safety monitoring and reporting;
(2) a CSIS, which is an electronic data capture (EDC) and study management system used to facilitate the collection of high-quality clinical research data;
(3) a specimen tracking and management system (STAMS), which is used by the hospital biobank to manage and keep track of human subject specimens and their testing; and
, which is used to de-link or de-identify personally identifiable information (PII), and which also allows the ability to associate the same patient across different studies. (Because of its unique features, the GUID can also be used for integrating de-identified datasets into a data repository.)
As an example, Figure 2 shows the full LHS cycle implementation of CIMS as used at NINDS for their intramural multiple sclerosis (MS) studies. Like most medical research institutions, patient care-related data were mainly collected in a HIS, in this case, the NIH Clinical Center's CRIS. To avoid any disruption of hospital operation and patient care, a separate data warehouse, the BTRIS, was created to provide clinical investigators with access to both identifiable data for subjects 
| The TCVGH information system
The CIMS described in the previous section was obtained from NIH/ 3.3 | The implementation and operation of LHS for the TCVGH dementia study
| Study management and data collection via CIMS
The multidepartment dementia study protocol was reviewed and received broad consensus after which it was submitted, reviewed, and approved by TCVGH IRB using the Taiwan PTMS system. 19 ), was also readily collected.
To ensure the quality of data, the CSIS was revised to collect and validate the essential clinical information for qualified cohorts. As shown in Figure 3 , routine clinical care data for dementia patients was collected from a de-identified research resource, called the "geriatrics database." This database is an internal patient data mart, which routinely collects the geriatrics study-related data from the main HIS in TCVGH. This geriatric database, which is essentially a hospital-based disease registry that collects data from patients with multiple neurological diseases, which also includes data from all dementia patients in this study. The geriatric database can be used as a research data mart after replacing the PII with a GUID, which was also used to integrate with research data, collected in CSIS. In addition to medical care and clinical research data collected, the mobile health data from the IoT (eg, wireless connected blood pressure monitors) may be collected and tracked in near real time in CSIS using web-based application programming interfaces (API). Some unstructured data, such as progress notes or radiology reports, can be processed through natural language processing (NLP) tools to be autocurated into CSIS. These capabilities greatly expand the ability of investigators and medical care staff to monitor and provide needed care for patients participating in research studies. The CSIS plays a key role in theTCVGH LHS implementation by facilitating not only the data capture process but also the quality assurance process.
With advanced sequencing technology, high throughput genomics data are now routinely generated at TCVGH laboratories using collected biospecimens in STAMS. In addition, the STAMS was enhanced to integrate clinical workflow from sample collection, bar-code generation and subsequent freezer storage, and routine lab sample processing into the study management pipeline. This greatly enhanced the clinical staff's efficiency and reduced errors during the clinical operations that supported this study. The specimen collection process was designed to use bar-code systems to ensure the sample data tracking quality. This bar-coded specimen identifier can be easily mapped to the GUID in a many-to-one relationship. This relationship can be relayed to any high throughput data generated from genomic studies conducted by bioinformatics PIs in the study. To make this research information available to researchers, the dementia registry portal was created to integrate CSIS and STAMS into a biobank information system to facilitate genotyping and phenotyping correlation analyses that are critical for precision medicine research. Both the processed and raw data of genomic studies were integrated in the dementia registry repository, which was used as an open and shared research resource. By linking the genotype (genomic data) with phenotype (clinical data), potential biomarkers for dementia and potential improved clinical care for study participants can be readily ascertained.
| Data standardization for data integration, sharing, and regulatory reporting
To reach the goal of data integration for sharing to accelerate precision medicine research, it is necessary to employ controlled vocabu- Clinical trial data for regulatory submissions in the United States and Japan are required to be standardized, based on CDISC standards.
Standards-compliant data can be directly archived in a "repository"
for data sharing and BIG data analytics. However, the effort required for after-the-fact data transformation is considerable and not easily attainable by investigator-initiated trials (IIT) wherein both funding and resources are limited. Therefore, it is important to implement and utilize standards before the start of a clinical trial.
The CIMS that supports the IIT in Taiwan was enhanced with a new "data standardization" function to make CDISC-compliant CRFs within the data collection module. 22 The study data can be collected in typical electronic data capture (EDC) form with the data elements being CDISC compliant. This new feature not only creates CDISCcompliant CRFs, which are useful in data interchange and sharing, but also in preparation of documents for regulatory submission. In addition, CSIS can import or export CRF data in an Operational Data Model (ODM) format, 23 which is a CDISC data transport standard. 
| Knowledge generation and LHS feedback process
Prior to new knowledge generation, which is a slow but essential process of any full-cycle of LHS, it is important for a clinical researcher to use collected research evidence to assess and improve patient care for better outcomes. The evidence collected in a hypothesis-driven research study or a clinical trial, such as the dementia registry study at TCVGH; the RWD, such as those recorded in the HIS or via IoT; the research data collected via standards such as CDISC-compliant CSIS CRFs; and high throughput data from the hospital laboratories must all be integrated and verified by a quality assurance or validation processes to support outcome assessment and knowledge discovery.
In a manner similar to that of the NIH/NINDS LHS implementations for neurological diseases, the datasets from TCVGH HIS data marts, CSIS databases, and biospecimen-generated data were integrated into a dementia registry using the GUID. research study, forming a knowledge feedback cycle to improve future medical care and achieving the goal of precision medicine research.
With this LHS implementation, we were able to use an integrated data source for the analyses and knowledge generation processes (D to K).
The newly generated knowledge provides optimized guidance for clinical practice (K to P). The data generated from the new clinical practice will again go into the dementia registry (P to D) for the next round of the learning health cycle. The integrated portal for data sharing and analysis of multiple data sources enabled "team science" research and greatly enhanced efficiency for collaboration in the dementia registry study at TCVGH toward achieving the goals of the LHS.
| Implications and lessons learned
A medical research center such as TCVGH has three primary objectives: medical practice, patient care, and research. The patient records in HIS and the health data collected by the IoT as part of a research study were considered to be RWD. RWD are useful but often, the quality is not satisfactory or not sufficient for clinical research.
The success of this large undertaking involved an effort to initiate precision medical research in a hospital care environment, using biospecimens and genomic data from consenting patients and inte- 
| CONCLUSIONS
The MS project and dementia registry are precision medicine research projects implemented by NIH and TCVGH, respectively. They have both demonstrated the feasibility of establishing a similar LHS implementation in a hospital research environment. Our successful strategy and experience can be readily replicated and customized to other projects in Taiwan, the United States, or around the world. Customizable learning cycles with CIMS can be further improved by inviting more interdisciplinary research teams or centers to join. For example, adding patients' reported outcomes research could be valuable in advancing personalized care. In addition, the LHS infrastructure could be easily expanded beyond TCVGH to include other veterans' care centers.
Once the LHS culture is established, patient care will gradually and continuously improve over time.
One potential concern of a project-based LHS is its sustainability.
For this reason, our LHS implementation was built on TCVGH's new precision medicine research, which maintains that an LHS is an efficient way to improve diagnosis and treatment through the use of RWD. When diagnosis and treatment become more precise, more patients will be attracted to TCVGH; this, in turn, will create more revenue to make the LHS sustainable. Currently, TCVGH is actively identifying other top diseases (such as diabetes and chronic kidney diseases) to include in new LHS implementations. This can help to ensure the sustainability of project-based LHSs.
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